Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors - PubMed (original) (raw)
Comparative Study
Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors
D Kufe et al. Hybridoma. 1984 Fall.
Abstract
We have defined a human breast tumor associated antigen using a murine monoclonal antibody (MAb DF3) prepared against a membrane-enriched fraction of a human breast carcinoma. This antigen has a MW of 290 kD and is detectable on the cell surface of human breast carcinoma cells using a live cell radioimmunoassay and fluorescence flow cytometry. More important, immunoperoxidase staining with MAb DF3 clearly distinguishes malignant and benign breast lesions. A cytoplasmic staining pattern has been observed with 40 of 51 (78%) breast carcinomas, but only one of 13 fibroadenoma or fibrocystic disease specimens. In contrast, reactivity of benign breast lesions with MAb DF3 primarily occurs along apical borders on ductules. These results demonstrate that the DF3 antigen is present on apical borders of more differentiated secretory mammary epithelial cells and in the cytosol of less differentiated cells.
Similar articles
- Monoclonal antibody DF3 correlates with tumor differentiation and hormone receptor status in breast cancer patients.
Lundy J, Thor A, Maenza R, Schlom J, Forouhar F, Testa M, Kufe D. Lundy J, et al. Breast Cancer Res Treat. 1985;5(3):269-76. doi: 10.1007/BF01806021. Breast Cancer Res Treat. 1985. PMID: 2992647 - Immunocytochemical reactivity of a mouse monoclonal antibody CDI 315B raised against human breast carcinoma.
Beketić-Oresković L, Sarcević B, Malenica B, Novak D. Beketić-Oresković L, et al. Neoplasma. 1993;40(2):69-74. Neoplasma. 1993. PMID: 8394515 - Reactivity of monoclonal antibody DF3 with a high molecular weight antigen expressed in human ovarian carcinomas.
Friedman EL, Hayes DF, Kufe DW. Friedman EL, et al. Cancer Res. 1986 Oct;46(10):5189-94. Cancer Res. 1986. PMID: 3530435 - Modulation of human tumor antigen expression.
Greiner JW, Hand PH, Colcher D, Weeks M, Thor A, Noguchi P, Pestka S, Schlom J. Greiner JW, et al. J Lab Clin Med. 1987 Mar;109(3):244-61. J Lab Clin Med. 1987. PMID: 2434589 Review.
Cited by
- Research progress of MUC1 in genitourinary cancers.
Mao W, Zhang H, Wang K, Geng J, Wu J. Mao W, et al. Cell Mol Biol Lett. 2024 Nov 3;29(1):135. doi: 10.1186/s11658-024-00654-x. Cell Mol Biol Lett. 2024. PMID: 39491020 Free PMC article. Review. - Cellular effects of tamoxifen in primary breast cancer.
Robertson JF, Ellis IO, Nicholson RI, Robins A, Bell J, Blamey RW. Robertson JF, et al. Breast Cancer Res Treat. 1992 Jan;20(2):117-23. doi: 10.1007/BF01834641. Breast Cancer Res Treat. 1992. PMID: 1554887 - MUC1-C oncoprotein induces TCF7L2 transcription factor activation and promotes cyclin D1 expression in human breast cancer cells.
Rajabi H, Ahmad R, Jin C, Kosugi M, Alam M, Joshi MD, Kufe D. Rajabi H, et al. J Biol Chem. 2012 Mar 23;287(13):10703-10713. doi: 10.1074/jbc.M111.323311. Epub 2012 Feb 8. J Biol Chem. 2012. PMID: 22318732 Free PMC article. - Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cells.
Raina D, Ahmad R, Rajabi H, Panchamoorthy G, Kharbanda S, Kufe D. Raina D, et al. Int J Oncol. 2012 May;40(5):1643-9. doi: 10.3892/ijo.2011.1308. Epub 2011 Dec 20. Int J Oncol. 2012. PMID: 22200620 Free PMC article. - The sweet and sour of serological glycoprotein tumor biomarker quantification.
Kuzmanov U, Kosanam H, Diamandis EP. Kuzmanov U, et al. BMC Med. 2013 Feb 7;11:31. doi: 10.1186/1741-7015-11-31. BMC Med. 2013. PMID: 23390961 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials